Medical Economics May 17, 2024
Analysts ponder value, transparency and the effects of the Inflation Reduction Act.
Drug research, sales and regulation continues to be a hot topic – and at times a complicated one – for physicians, patients and leaders in the pharmaceutical industry.
Two experts offered their explanations and a few predictions in “Solving the US drug pricing problem,” a panel discussion held May 16, 2024, in the Financial Times US Pharma and Biotech Summit. Sarah Emond, MPP, president and CEO of the Institute for Clinical and Economic Review, and John O’Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council, offered their views speaking with Financial Times Science Editor Michael Peel.
As of 2024, some industry observers say the payment system...
Today's Sponsors
Today's Sponsor